On March 9, 2025, MeiraGTx Holdings plc entered into a strategic collaboration with Hologen Limited, receiving an upfront payment of $200 million and potential additional funding of up to $230 million for gene therapy development. The collaboration includes licensing agreements for various investigational therapies and a minority interest in MeiraGTx's manufacturing business.